PortalPublikationenConcomitant Tricuspid Repair in Patients with Degenerative M...

Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation

Standard

Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. / Gammie, James S; Chu, Michael W A; Falk, Volkmar; Overbey, Jessica R; Moskowitz, Alan J; Gillinov, Marc; Mack, Michael J; Voisine, Pierre; Krane, Markus; Yerokun, Babatunde; Bowdish, Michael E; Conradi, Lenard; Bolling, Steven F; Miller, Marissa A; Taddei-Peters, Wendy C; Jeffries, Neal O; Parides, Michael K; Weisel, Richard; Jessup, Mariell; Rose, Eric A; Mullen, John C; Raymond, Samantha; Moquete, Ellen G; O'Sullivan, Karen; Marks, Mary E; Iribarne, Alexander; Beyersdorf, Friedhelm; Borger, Michael A; Geirsson, Arnar; Bagiella, Emilia; Hung, Judy; Gelijns, Annetine C; O'Gara, Patrick T; Ailawadi, Gorav; CTSN Investigators.

in: NEW ENGL J MED, Jahrgang 386, Nr. 4, 27.01.2022, S. 327-339.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gammie, JS, Chu, MWA, Falk, V, Overbey, JR, Moskowitz, AJ, Gillinov, M, Mack, MJ, Voisine, P, Krane, M, Yerokun, B, Bowdish, ME, Conradi, L, Bolling, SF, Miller, MA, Taddei-Peters, WC, Jeffries, NO, Parides, MK, Weisel, R, Jessup, M, Rose, EA, Mullen, JC, Raymond, S, Moquete, EG, O'Sullivan, K, Marks, ME, Iribarne, A, Beyersdorf, F, Borger, MA, Geirsson, A, Bagiella, E, Hung, J, Gelijns, AC, O'Gara, PT, Ailawadi, G & CTSN Investigators 2022, 'Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation', NEW ENGL J MED, Jg. 386, Nr. 4, S. 327-339. https://doi.org/10.1056/NEJMoa2115961

APA

Gammie, J. S., Chu, M. W. A., Falk, V., Overbey, J. R., Moskowitz, A. J., Gillinov, M., Mack, M. J., Voisine, P., Krane, M., Yerokun, B., Bowdish, M. E., Conradi, L., Bolling, S. F., Miller, M. A., Taddei-Peters, W. C., Jeffries, N. O., Parides, M. K., Weisel, R., Jessup, M., ... CTSN Investigators (2022). Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. NEW ENGL J MED, 386(4), 327-339. https://doi.org/10.1056/NEJMoa2115961

Vancouver

Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M et al. Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. NEW ENGL J MED. 2022 Jan 27;386(4):327-339. https://doi.org/10.1056/NEJMoa2115961

Bibtex

@article{3cbc267694954df79ca876a49ab99b51,
title = "Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation",
abstract = "BACKGROUND: Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or less-than-moderate regurgitation with annular dilatation.METHODS: We randomly assigned 401 patients who were undergoing mitral-valve surgery for degenerative mitral regurgitation to receive a procedure with or without tricuspid annuloplasty (TA). The primary 2-year end point was a composite of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation by two grades from baseline or the presence of severe tricuspid regurgitation, or death.RESULTS: Patients who underwent mitral-valve surgery plus TA had fewer primary-end-point events than those who underwent mitral-valve surgery alone (3.9% vs. 10.2%) (relative risk, 0.37; 95% confidence interval [CI], 0.16 to 0.86; P = 0.02). Two-year mortality was 3.2% in the surgery-plus-TA group and 4.5% in the surgery-alone group (relative risk, 0.69; 95% CI, 0.25 to 1.88). The 2-year prevalence of progression of tricuspid regurgitation was lower in the surgery-plus-TA group than in the surgery-alone group (0.6% vs. 6.1%; relative risk, 0.09; 95% CI, 0.01 to 0.69). The frequencies of major adverse cardiac and cerebrovascular events, functional status, and quality of life were similar in the two groups at 2 years, although the incidence of permanent pacemaker implantation was higher in the surgery-plus-TA group than in the surgery-alone group (14.1% vs. 2.5%; rate ratio, 5.75; 95% CI, 2.27 to 14.60).CONCLUSIONS: Among patients undergoing mitral-valve surgery, those who also received TA had a lower incidence of a primary-end-point event than those who underwent mitral-valve surgery alone at 2 years, a reduction that was driven by less frequent progression to severe tricuspid regurgitation. Tricuspid repair resulted in more frequent permanent pacemaker implantation. Whether reduced progression of tricuspid regurgitation results in long-term clinical benefit can be determined only with longer follow-up. (Funded by the National Heart, Lung, and Blood Institute and the German Center for Cardiovascular Research; ClinicalTrials.gov number, NCT02675244.).",
keywords = "Aged, Cardiac Valve Annuloplasty, Dilatation, Pathologic, Disease Progression, Female, Follow-Up Studies, Humans, Intention to Treat Analysis, Male, Mitral Valve/surgery, Mitral Valve Insufficiency/complications, Pacemaker, Artificial, Postoperative Complications, Quality of Life, Reoperation, Survival Analysis, Tricuspid Valve/pathology, Tricuspid Valve Insufficiency/complications",
author = "Gammie, {James S} and Chu, {Michael W A} and Volkmar Falk and Overbey, {Jessica R} and Moskowitz, {Alan J} and Marc Gillinov and Mack, {Michael J} and Pierre Voisine and Markus Krane and Babatunde Yerokun and Bowdish, {Michael E} and Lenard Conradi and Bolling, {Steven F} and Miller, {Marissa A} and Taddei-Peters, {Wendy C} and Jeffries, {Neal O} and Parides, {Michael K} and Richard Weisel and Mariell Jessup and Rose, {Eric A} and Mullen, {John C} and Samantha Raymond and Moquete, {Ellen G} and Karen O'Sullivan and Marks, {Mary E} and Alexander Iribarne and Friedhelm Beyersdorf and Borger, {Michael A} and Arnar Geirsson and Emilia Bagiella and Judy Hung and Gelijns, {Annetine C} and O'Gara, {Patrick T} and Gorav Ailawadi and {CTSN Investigators}",
note = "Copyright {\textcopyright} 2021 Massachusetts Medical Society.",
year = "2022",
month = jan,
day = "27",
doi = "10.1056/NEJMoa2115961",
language = "English",
volume = "386",
pages = "327--339",
journal = "NEW ENGL J MED",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "4",

}

RIS

TY - JOUR

T1 - Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation

AU - Gammie, James S

AU - Chu, Michael W A

AU - Falk, Volkmar

AU - Overbey, Jessica R

AU - Moskowitz, Alan J

AU - Gillinov, Marc

AU - Mack, Michael J

AU - Voisine, Pierre

AU - Krane, Markus

AU - Yerokun, Babatunde

AU - Bowdish, Michael E

AU - Conradi, Lenard

AU - Bolling, Steven F

AU - Miller, Marissa A

AU - Taddei-Peters, Wendy C

AU - Jeffries, Neal O

AU - Parides, Michael K

AU - Weisel, Richard

AU - Jessup, Mariell

AU - Rose, Eric A

AU - Mullen, John C

AU - Raymond, Samantha

AU - Moquete, Ellen G

AU - O'Sullivan, Karen

AU - Marks, Mary E

AU - Iribarne, Alexander

AU - Beyersdorf, Friedhelm

AU - Borger, Michael A

AU - Geirsson, Arnar

AU - Bagiella, Emilia

AU - Hung, Judy

AU - Gelijns, Annetine C

AU - O'Gara, Patrick T

AU - Ailawadi, Gorav

AU - CTSN Investigators

N1 - Copyright © 2021 Massachusetts Medical Society.

PY - 2022/1/27

Y1 - 2022/1/27

N2 - BACKGROUND: Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or less-than-moderate regurgitation with annular dilatation.METHODS: We randomly assigned 401 patients who were undergoing mitral-valve surgery for degenerative mitral regurgitation to receive a procedure with or without tricuspid annuloplasty (TA). The primary 2-year end point was a composite of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation by two grades from baseline or the presence of severe tricuspid regurgitation, or death.RESULTS: Patients who underwent mitral-valve surgery plus TA had fewer primary-end-point events than those who underwent mitral-valve surgery alone (3.9% vs. 10.2%) (relative risk, 0.37; 95% confidence interval [CI], 0.16 to 0.86; P = 0.02). Two-year mortality was 3.2% in the surgery-plus-TA group and 4.5% in the surgery-alone group (relative risk, 0.69; 95% CI, 0.25 to 1.88). The 2-year prevalence of progression of tricuspid regurgitation was lower in the surgery-plus-TA group than in the surgery-alone group (0.6% vs. 6.1%; relative risk, 0.09; 95% CI, 0.01 to 0.69). The frequencies of major adverse cardiac and cerebrovascular events, functional status, and quality of life were similar in the two groups at 2 years, although the incidence of permanent pacemaker implantation was higher in the surgery-plus-TA group than in the surgery-alone group (14.1% vs. 2.5%; rate ratio, 5.75; 95% CI, 2.27 to 14.60).CONCLUSIONS: Among patients undergoing mitral-valve surgery, those who also received TA had a lower incidence of a primary-end-point event than those who underwent mitral-valve surgery alone at 2 years, a reduction that was driven by less frequent progression to severe tricuspid regurgitation. Tricuspid repair resulted in more frequent permanent pacemaker implantation. Whether reduced progression of tricuspid regurgitation results in long-term clinical benefit can be determined only with longer follow-up. (Funded by the National Heart, Lung, and Blood Institute and the German Center for Cardiovascular Research; ClinicalTrials.gov number, NCT02675244.).

AB - BACKGROUND: Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or less-than-moderate regurgitation with annular dilatation.METHODS: We randomly assigned 401 patients who were undergoing mitral-valve surgery for degenerative mitral regurgitation to receive a procedure with or without tricuspid annuloplasty (TA). The primary 2-year end point was a composite of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation by two grades from baseline or the presence of severe tricuspid regurgitation, or death.RESULTS: Patients who underwent mitral-valve surgery plus TA had fewer primary-end-point events than those who underwent mitral-valve surgery alone (3.9% vs. 10.2%) (relative risk, 0.37; 95% confidence interval [CI], 0.16 to 0.86; P = 0.02). Two-year mortality was 3.2% in the surgery-plus-TA group and 4.5% in the surgery-alone group (relative risk, 0.69; 95% CI, 0.25 to 1.88). The 2-year prevalence of progression of tricuspid regurgitation was lower in the surgery-plus-TA group than in the surgery-alone group (0.6% vs. 6.1%; relative risk, 0.09; 95% CI, 0.01 to 0.69). The frequencies of major adverse cardiac and cerebrovascular events, functional status, and quality of life were similar in the two groups at 2 years, although the incidence of permanent pacemaker implantation was higher in the surgery-plus-TA group than in the surgery-alone group (14.1% vs. 2.5%; rate ratio, 5.75; 95% CI, 2.27 to 14.60).CONCLUSIONS: Among patients undergoing mitral-valve surgery, those who also received TA had a lower incidence of a primary-end-point event than those who underwent mitral-valve surgery alone at 2 years, a reduction that was driven by less frequent progression to severe tricuspid regurgitation. Tricuspid repair resulted in more frequent permanent pacemaker implantation. Whether reduced progression of tricuspid regurgitation results in long-term clinical benefit can be determined only with longer follow-up. (Funded by the National Heart, Lung, and Blood Institute and the German Center for Cardiovascular Research; ClinicalTrials.gov number, NCT02675244.).

KW - Aged

KW - Cardiac Valve Annuloplasty

KW - Dilatation, Pathologic

KW - Disease Progression

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Intention to Treat Analysis

KW - Male

KW - Mitral Valve/surgery

KW - Mitral Valve Insufficiency/complications

KW - Pacemaker, Artificial

KW - Postoperative Complications

KW - Quality of Life

KW - Reoperation

KW - Survival Analysis

KW - Tricuspid Valve/pathology

KW - Tricuspid Valve Insufficiency/complications

U2 - 10.1056/NEJMoa2115961

DO - 10.1056/NEJMoa2115961

M3 - SCORING: Journal article

C2 - 34767705

VL - 386

SP - 327

EP - 339

JO - NEW ENGL J MED

JF - NEW ENGL J MED

SN - 0028-4793

IS - 4

ER -